Chemotherapy News and Research

Latest Chemotherapy News and Research

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

Viewpoints: Mcconnell, Wasserman Schultz, Barasso on Obamacare's 4th anniversary; defending surgeon general nominee

Viewpoints: Mcconnell, Wasserman Schultz, Barasso on Obamacare's 4th anniversary; defending surgeon general nominee

High-volume medical centers improve gynecologic cancer survival

High-volume medical centers improve gynecologic cancer survival

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

New technology gives tool to examine membrane proteins in natural environment of human cell

New technology gives tool to examine membrane proteins in natural environment of human cell

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Faster DNA sequencing techniques more likely to improve care for patients with breast cancer

Faster DNA sequencing techniques more likely to improve care for patients with breast cancer

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

Measuring circulating tumor cells may help better predict prostate cancer survival

Measuring circulating tumor cells may help better predict prostate cancer survival

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Researchers uncover cause of rare type of ovarian cancer that strikes girls and young women

Researchers uncover cause of rare type of ovarian cancer that strikes girls and young women

Breast cancer screening in older women

Breast cancer screening in older women

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

ZL105 drug could potentially replace currently used anticancer drugs, study finds

ZL105 drug could potentially replace currently used anticancer drugs, study finds

Viewpoints: Romneycare and cutting workers; Fla.'s surprising ruling on malpractice reform

Viewpoints: Romneycare and cutting workers; Fla.'s surprising ruling on malpractice reform

Misplaced protein provides promising drug target for kidney cancer

Misplaced protein provides promising drug target for kidney cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.